Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Services
  • Revvity Omics Services
  • Revvity Omics Clinical Services
    • Revvity Omics Clinical Services
    • Revvity Omics Pharma Services
  • Proactive Testing
    • Cytogenomics
    • Global Laboratory Network
    • Metabolic Testing
    • Newborn Screening Services
    • Prenatal Screening Services
    • Proactive Testing
    • Rare Disease Testing
    • Specialized and Customized Assays
    • Sponsored Testing Programs
  • Proactive Whole Genome Sequencing
    • Proactive Whole Exome Sequencing
    • Proactive Whole Genome Sequencing
    • Type 1 Diabetes Early Detection

Proactive Whole Genome Sequencing


Empowering early decisions with genomic insight

Proactive Whole Genome Sequencing

Whole genome sequencing (WGS) is revolutionizing prenatal and postnatal care. By analyzing an individual’s DNA before clinical symptoms emerge, WGS allows for early detection of genetic conditions, equipping families and healthcare providers with tools for proactive, personalized healthcare. This proactive approach enables informed, timely decisions that can significantly improve health outcomes.

Order testing Contact us
Resources
  • Test requisition form
""

Findings included in proactive genome sequencing

  • ACMG Recommended Secondary Findings - pathogenic and likely pathogenic variants in genes recommended for reporting based on well-defined, highly-penetrant phenotypes with clinical actionability.
  • Pharmacogenetic Variants - select allele haplotypes recommended by the Association for Molecular Pathology pharmacogenomics working group and classified as Clinical Pharmacogenetics Implementation Consortium (CPIC) level A and PharmGKB level 1A.
  • Carrier Status - 330+ genes associated with disorders whose inheritance pattern is autosomal recessive or X-linked.
  • Diagnostic findings in all disease-associated genes - pathogenic and likely pathogenic variants are reported in genes associated with disease.

Findings included in proactive prenatal genome sequencing

For proactive prenatal genome sequencing, only pathogenic and likely pathogenic findings in the ACMG recommended secondary findings and diagnostic results in disease-associated genes will be available for opt-in. Pediatric-onset diagnostic findings will be reported in the selected categories.

Maternal cell contamination (MCC) is offered as a stand-alone test. It is required for testing of samples derived from amniotic fluid and chorionic villi. MCC studies can be requested on other prenatal/fetal samples at the ordering provider's discretion.

""

Testing options

Proactive Testing
Proactive Ultrarapid Whole Genome Sequencing, Proband only
Test Code D2010H
Turn Around Time 5 - 8 days
Order Test
Proactive Whole Genome Sequencing, Proband only
Test Code D2000H
Turn Around Time 4 weeks
Order Test
Proactive prenatal testing
STAT Proactive Prenatal Whole Genome Sequencing, DUO
Test Code D2330HE
Turn Around Time 5 - 8 days
Order Test
STAT Proactive Prenatal Whole Genome Sequencing, Proband ONLY
Test Code D2010HE
Turn Around Time 5 - 8 days
Order Test
STAT Proactive Prenatal Whole Genome Sequencing, TRIO
Test Code D2310HE
Turn Around Time 5 - 8 days
Order Test

How to order

Step 1

Test selection and place order

Step 2

Specimen collection and Shipment

Step 3

Sample shipment

Learn more

How to order

Test selection and place order

Select the correct test for your patient, and fill out the appropriate Test requisition form.

  • Please make sure that all sections are completed, and that the patient has signed an informed consent form.
  • If a TRIO is ordered, please feel out the “Familial Information” section for tracking purposes.
Collect a sample

Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs. If you do not have a kit available in your office, please contact us here and we can have one sent out to your office.

  • Ensure that all samples are labeled with the patient name and date of birth.
  • For Trio tests, parental and/or family member samples can be submitted separately from the patient/proband, if needed. Additional samples must be received by the laboratory within three weeks of the original patient/proband submission.
  • All parental/family member samples must be submitted with a fully completed requisition and informed consent form, complete with both physician and patient signatures.
Send a sample

Package the patient sample, informed consent form, and test requisition form back into the test kit, and utilize the included pre-paid shipping label to return the kit to Revvity Omics for processing.

Close

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.

Contact Revvity Omics for more information

Contact us
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.